Welcome!

News Feed Item

Next-Generation Biologics R&D, Industry and Market 2014-2024

LONDON, April 12, 2014 /PRNewswire/ --

Emerging biological drugs - discover R&D, business analysis, and revenue forecasts

What's the future of biologics, especially new drug classes? Now get the latest technological and commercial analysis. Staying ahead in data and knowledge, you benefit your authority. And you explore trends, developments, results, opportunities, and sales predictions.

So visiongain's new report shows you what's possible for biological drugs - their next phase. There avoid missing out. Instead find progress in that industry and market, discovering expected progress and revenues. See now how you can gain.

New biotechnological medicines will benefit patients and pharmaceutical companies. Read on to explore those therapies, hearing how high revenues can go.

Forecasting and other information showing the most lucrative possibilities for treatments
That study gives you sales forecasts to 2024 at overall world, submarket, product, and national level. See what the future holds, assessing gains for developers and producers.

Many opportunities exist. And besides giving revenue predictions, that new analysis shows recent results, growth rates, and market shares. There you discover 94 tables, 55 charts, and two interviews with authorities in the biopharmaceuticals sector.

And the following sections explain what our new investigation gives you.

Analyses exclusive to that study, showing the most important commercial potentials
In our report you get data found nowhere else. Discover what's really going on. Our forecasting system goes to the core of the biopharmaceutical industry's sales potential like no other work, giving revenue predictions and their meanings.

That analysis benefits your plans, decisions, and influence by interpreting medical needs, R&D, and companies' abilities. You hear what's happening, then, assessing likely gains.

So find in those analyses where potential and money lie, also saving time, worry, and effort.

Prospects for the world market and submarkets - what's possible for pharma biotechnology?
There, in our report, discover overall world sales to 2024 for biologics and new therapies, with discussions.

Also get individual revenue predictions to 2024 for 17 next-generation biologic submarkets at world level: 

• Regenerative medicine, with submarket breakdowns for tissue engineering, stem cells, and gene therapies
• Antibodies, including monoclonal antibodies (mAbs), with sub-forecasting for antibody-drug conjugates (ADCs), engineered, and bispecific agents
• Antibody fragments and antibody-like protein (ALP) platforms
• Biosimilars (follow-on protein products).

To see a report overview please email Sara Peerun on [email protected]

And discover other segments' forecasts to 2024: 

• Insulins, with submarkets for ultra-long acting, oral, and ultra-rapid-acting insulins
• Growth hormones
• Recombinant coagulation factors
• Other types of next-stage therapeutic proteins.

Next-generation biologics that treat new indications will be launched within 10 years. And you assess outlooks for that expansion in trade, hearing where you could gain.

Our study also explores competition. There you see what's happening for developers, producers, and sellers of new-generation biologics, understanding challenges, trends, and outlooks.

That work also splits its overall world market into leading products, showing where you could profit from new and improved biotech medicines.

Product forecasts for new forms, variations, and uses of biological therapy
How will individual drugs perform to 2024 at world level? Our report predicts revenues of seven top brands:

• Adcetris
• Kadcyla
• Gazyva
• Tresiba
• Afrezza
• Plegridy
• Eloctate.

There you find products and years with highest forecasted sales. And the report predicts those seven therapies will earn combined revenue of more than $10bn in 2024.

You also examine competitors. See what's happening, then, understanding challenges, trends, competition, and opportunities. And here's what that study's author said:

"Next-generation biologics will address shortcomings in current therapies, including inconvenient dosing and concerns over side effects. Developmental trends include sustained release, for less-frequent dosing, and reformulations for oral and topical administration."

That work also gives geographical revenue forecasts.

Healthcare in national markets - what outlooks for business in new biopharma products?
Advances in biotechnology and healthcare expand use of novel biological drugs in developed and developing countries. Also opportunities exist for newer treatments.

And our analyses show you individual revenue forecasts to 2024 for nine national markets: 

United States (US)
Japan
• EU leaders - Germany, France, the UK, Italy, and Spain (EU5)
China
India.

There you hear about the best sales potentials, appraising national opportunities for next-generation biologicals. See where and how you can profit.

For treating people and saving lives, you explore progress, needs, and possibilities. Find how pharma companies satisfy those demands, also assessing expected financial gains.

And what events influence the biologics industry? What's the outlook for tackling serious diseases? Our work shows you, discussing trends, challenges, and opportunities.

Market forces and issues - what affects biopharma developers, producers, and sellers?
The report explains trends, processes, and events affecting the biopharma industry and market from 2014, including these forces:

• Limitations of existing biologics
• Promise of next-generation biologics, and product launches
• Extension of half-life - pegylation and other technologies
• Demand rising for biological therapies
• Contract manufacturers (CMOs) serving those developmental needs and trends.

To see a report overview please email Sara Peerun on [email protected]

And you explore these influences, among others: 

• Disease incidence affecting demand for those more-developed medicines
• Improvements in therapeutic antibodies, including targeted cytotoxic therapies
• R&D pipelines - e.g. for immunotoxins - including agents in clinical development
• Biosimilar insulins likely from 2015 - transformation of that market
• Effects of rising incidence rates in cancer, diabetes, and cardiovascular disorders.

There discover what the future holds. You explore political, economic, social, and technological questions. See too how R&D helps companies benefit patients.

So you explore what progress, trends, and prospects mean. And discover what helps and what hinders players in that healthcare industry, affecting participants' results.

Biological drug technology and applications - companies and 2018 market value
So what happens next? From 2014, novel and biosimilar treatments will benefit patients, doctors, and payers. Those advances will encourage investments, medical progress, and higher revenues from more-advanced biological drugs.

And our study predicts the next-generation biologics market will reach $12.17bn worldwide in 2018, and then multiply in revenues to 2024. See what's possible and what you can gain.

That work also explores activities of these leading companies, among many other firms: 

• Roche
• Eli Lilly
• Novo Nordisk
• Sanofi
• Pfizer
• Kyowa Hakko Kirin
• Baxter International.

In that market, large pharmaceutical corporations and smaller biopharma specialists can win. See how.

And you find 235 organisations covered. You also get interviews with two companies in the industry, helping you stay ahead. See, then, what the future holds.

Ways Next-Generation Biologics: R&D, Industry and Market 2014-2024 helps
In three main ways our new investigation helps you gain recognition for insight, with data found only there:

• Revenues to 2024 at world level, for 17 submarkets, and 7 products - explore outlooks for production, marketing, and sales
• Forecasts to 2024 for 9 national markets in North America, Europe, and Asia - assess countries for revenues and sales expansions
• Prospects for established competitors, rising companies, and new entrants - investigate portfolios, results, strategies, R&D, and opinions from interviews.

Knowledge there found nowhere else, helping your searches, analyses, and planning
Our new report provides competitive intelligence, showing where progress and money lie.

That work's purpose is to predict sales results with maximum clarity, applicability, and detail. And its research and analyses identify and explain commercial prospects. Now you explore the biological drug industry's future through data exclusive to that study.

So our analysis helps you avoid falling behind in information or missing opportunity. Also it lets you save time and effort. And now your choice could benefit your plans, decisions, and authority - increasing your chances of finding competitive advantages.

Biopharmaceutical knowledge - getting our new report now helps you stay ahead
By trying our new study on emerging biologicals you explore trends, R&D, and sales predictions. There stay ahead - please get that report here now.

To request a report overview please email Sara Peerun at [email protected] or call Tel : +44 (0) 20 7336 6100

Or click on https://www.visiongain.com/Report/1235/Next-Generation-Biologics-R-D-Industry-and-Market-2014-2024

Companies Listed in this report: 

3SBio
Aastrom Biosciences
AbbVie
Abcam
Ablynx
ADC Therapeutics
Adnexus (part of Bristol-Myers Squibb)
Adocia
Advanced Cell Technology
Advantagene
Affibody
Agence Nationale de sécurité du Médicament et des produits de santé (ANSM)
Alcon (part of Novartis)
Alexion Pharmaceuticals
Alfacell (now Tamir Biotechnology)
Alkermes
Allergan
Allozyne
Ambrx
Amgen
AMRI
AnGes
Applied Genetic Technologies (AGTC)
Ark Therapeutics
Astellas Pharma
AstraZeneca
Athersys
Avita Medical
Babraham Institute
Baxter International
Bayer Healthcare
Belrose Pharma
Benda Pharmaceutical
Biocad
BioCancell Therapeutics
Biocon
Biodel
Biogen Idec
Bioheart
BioMarin Pharmaceutical
Biopartners (part of Bioton)
Biotest
Bioton
BioVex Group (part of Amgen)
BioWa (part of Kyowa Hakko Kirin)
bluebird bio
Boehringer Ingelheim
BrainStorm Cell Therapeutics
Bristol-Myers Squibb
Capricor Therapeutics
Cardio3 BioSciences
Cardium Therapeutics
Catalent Pharma Solutions
Celgene
Celladon
CellCoTec
Celldex Therapeutics
Cellerant Therapeutics
Cellular Dynamics International (CDI)
Centers for Disease Prevention and Control (CDC) [US]
Cephalon (part of Teva)
CEPiA (part of Sanofi)
Ceregene
Chatham Therapeutics
Chiesi Farmaceutici
Children's Hospital of Philadelphia (CHOP)
China Food and Drug Administration (CFDA)
Chugai (part of Roche)
Civitas Therapeutics
Clayton Biotechnologies
Cold Genesys
Concortis
Covagen
Crescendo Biologics
Critical Pharmaceuticals
CSL Behring
CytoMedix
Cytori Therapeutics
Dance Biopharm
Delenex Therapeutics
Depuy Mitek (part of J&J)
Diabetology
Dr. Reddy's Laboratories
Duke University
Duke University Hospital
Dyax
Eddingpharm
EGEN
Eisai
Elan Pharmaceuticals (now part of Perrigo Company)
Eli Lilly
EMA's Committee for Medicinal Products for Human Use (CHMP)
Emisphere
Enzon Pharmaceuticals
EnzymeRx
Epitomics (part of Abcam)
ESBATech (part of Novartis)
European Commission
European Medicines Agency (EMA)
Flamel Technologies
Food and Drug Administration (FDA) [US]
Fresenius Biotech (now named Neovii Biotech, part of Neopharm)
Fuji Pharma
Fujifilm Diosynth Biotechnologies
Gamida Cell
Genentech (part of Roche)
Generex Biotechnology
Genzyme (part of Sanofi)
Geron
GlycoExpress
Glycotope
GSK
Halozyme Therapeutics
Hanmi Pharmaceutical
Health Canada
Hikma Pharmaceuticals
Histogenics
Humacyte
Human Stem Cells Institute (HSCI)
Igenica
ImmunoGen
Immunomedics
Innovent Biologics
Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Germany]
Integra LifeSciences
International Diabetes Federation (IDF)
Introgen Therapeutics
J&J
Jain Foundation
JCR Pharmaceuticals
Juventas Therapeutics
Karolinska Institute
Kyowa Hakko Kirin
LG Life Sciences
LifeCell
Lonza
MacroGenics
MannKind
MedImmune (part of AstraZeneca)
Merck & Co.
Merck KGaA
Merrimack Pharmaceuticals
Merrion Pharmaceuticals
Mersana Therapeutics
Mesoblast
Micromet (part of Amgen)
Ministry of Health, Labor and Welfare (MHLW) [Japan]
Mitsubishi Tanabe Pharma
Mochida Pharmaceutical
Molecular Partners
Moorfields Eye Hospital [UK]
MorphoSys
National Cancer Institute (NCI) [US]
National Health Service (NHS) [UK]
National Institute for Health and Care Excellence (NICE) [UK]
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) [US]
Neopharm Group
NeoStem
NeuralStem
Nippon Kayaku
Novartis
Novo Nordisk
Nuron Biotech
NuVasive
OncoSec Medical
OPKO Health
Oramed Pharmaceuticals
Organogenesis
Organovo
Orthofix
Osiris Therapeutics
PeriphaGen Holdings
Perrigo Company
Pfizer
Pieris
Piramal Group
Progenics Pharmaceuticals
Prolor Biotech (part of OPKO Health)
Rani Therapeutics
ratiopharm (part of Teva)
Redwood Bioscience
Regeneron Pharmaceuticals
Reliance Life Sciences
ReNeuron
RIKEN [Japan]
Roche
Roche Glycart (part of Roche)
Royal Institute of Technology [Sweden]
Russian Ministry of Healthcare (Minzdrav)
SAFC
Sandoz (part of Novartis)
Sanofi
Scottish Medicines Consortium (SMC)
Seattle Genetics
Shanghai Sunway Biotech
Shenzhen SiBiono GeneTech (part of Benda)
Shreya Life Sciences
SironRX Therapeutics
Skye Orthobiologics
Sorrento Therapeutics
Sotex PharmFirm
Spark Therapeutics
Spectrum Pharmaceuticals
Spirogen (part of AstraZeneca)
Stanford University
Stelis Biopharmaceuticals (part of Strides Arcolab)
StemCells
Stempeutics Research
Strativa Pharmaceuticals
Strides Arcolab
Sutro Biopharma
Swedish Orphan Biovitrum (Sobi)
Swiss Federal Institute of Technology
Symphogen
Synthon
Synthon Biopharmaceuticals (part of Synthon)
Takeda Pharmaceutical Company
Teva Pharmaceutical Industries
Thermalin Diabetes
Tianjin International Joint Academy of Bio-medicine
TiGenix
University of Toronto
TRION Pharma
UCB
University of California, San Francisco (UCSF)
UniQure
USV
VBL Therapeutics
Versartis
viDA Therapeutics
VX Pharma
World Bank Group
World Cancer Research Fund (WCRF)
World Health Organization (WHO)
Wyeth (part of Pfizer)
Xencor
Xeris Pharmaceuticals
Yale School of Medicine
Zydus Cadila

To see a report overview please email Sara Peerun on [email protected]

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
As data explodes in quantity, importance and from new sources, the need for managing and protecting data residing across physical, virtual, and cloud environments grow with it. Managing data includes protecting it, indexing and classifying it for true, long-term management, compliance and E-Discovery. Commvault can ensure this with a single pane of glass solution – whether in a private cloud, a Service Provider delivered public cloud or a hybrid cloud environment – across the heterogeneous enter...
"IoT is going to be a huge industry with a lot of value for end users, for industries, for consumers, for manufacturers. How can we use cloud to effectively manage IoT applications," stated Ian Khan, Innovation & Marketing Manager at Solgeniakhela, in this SYS-CON.tv interview at @ThingsExpo, held November 3-5, 2015, at the Santa Clara Convention Center in Santa Clara, CA.
Today we can collect lots and lots of performance data. We build beautiful dashboards and even have fancy query languages to access and transform the data. Still performance data is a secret language only a couple of people understand. The more business becomes digital the more stakeholders are interested in this data including how it relates to business. Some of these people have never used a monitoring tool before. They have a question on their mind like “How is my application doing” but no id...
@GonzalezCarmen has been ranked the Number One Influencer and @ThingsExpo has been named the Number One Brand in the “M2M 2016: Top 100 Influencers and Brands” by Onalytica. Onalytica analyzed tweets over the last 6 months mentioning the keywords M2M OR “Machine to Machine.” They then identified the top 100 most influential brands and individuals leading the discussion on Twitter.
In IT, we sometimes coin terms for things before we know exactly what they are and how they’ll be used. The resulting terms may capture a common set of aspirations and goals – as “cloud” did broadly for on-demand, self-service, and flexible computing. But such a term can also lump together diverse and even competing practices, technologies, and priorities to the point where important distinctions are glossed over and lost.
Predictive analytics tools monitor, report, and troubleshoot in order to make proactive decisions about the health, performance, and utilization of storage. Most enterprises combine cloud and on-premise storage, resulting in blended environments of physical, virtual, cloud, and other platforms, which justifies more sophisticated storage analytics. In his session at 18th Cloud Expo, Peter McCallum, Vice President of Datacenter Solutions at FalconStor, discussed using predictive analytics to mon...
All clouds are not equal. To succeed in a DevOps context, organizations should plan to develop/deploy apps across a choice of on-premise and public clouds simultaneously depending on the business needs. This is where the concept of the Lean Cloud comes in - resting on the idea that you often need to relocate your app modules over their life cycles for both innovation and operational efficiency in the cloud. In his session at @DevOpsSummit at19th Cloud Expo, Valentin (Val) Bercovici, CTO of Soli...
Information technology is an industry that has always experienced change, and the dramatic change sweeping across the industry today could not be truthfully described as the first time we've seen such widespread change impacting customer investments. However, the rate of the change, and the potential outcomes from today's digital transformation has the distinct potential to separate the industry into two camps: Organizations that see the change coming, embrace it, and successful leverage it; and...
Without a clear strategy for cost control and an architecture designed with cloud services in mind, costs and operational performance can quickly get out of control. To avoid multiple architectural redesigns requires extensive thought and planning. Boundary (now part of BMC) launched a new public-facing multi-tenant high resolution monitoring service on Amazon AWS two years ago, facing challenges and learning best practices in the early days of the new service. In his session at 19th Cloud Exp...
Extracting business value from Internet of Things (IoT) data doesn’t happen overnight. There are several requirements that must be satisfied, including IoT device enablement, data analysis, real-time detection of complex events and automated orchestration of actions. Unfortunately, too many companies fall short in achieving their business goals by implementing incomplete solutions or not focusing on tangible use cases. In his general session at @ThingsExpo, Dave McCarthy, Director of Products...
Regulatory requirements exist to promote the controlled sharing of information, while protecting the privacy and/or security of the information. Regulations for each type of information have their own set of rules, policies, and guidelines. Cloud Service Providers (CSP) are faced with increasing demand for services at decreasing prices. Demonstrating and maintaining compliance with regulations is a nontrivial task and doing so against numerous sets of regulatory requirements can be daunting task...
Fact: storage performance problems have only gotten more complicated, as applications not only have become largely virtualized, but also have moved to cloud-based infrastructures. Storage performance in virtualized environments isn’t just about IOPS anymore. Instead, you need to guarantee performance for individual VMs, helping applications maintain performance as the number of VMs continues to go up in real time. In his session at Cloud Expo, Dhiraj Sehgal, Product and Marketing at Tintri, sha...
The Internet of Things (IoT) promises to simplify and streamline our lives by automating routine tasks that distract us from our goals. This promise is based on the ubiquitous deployment of smart, connected devices that link everything from industrial control systems to automobiles to refrigerators. Unfortunately, comparatively few of the devices currently deployed have been developed with an eye toward security, and as the DDoS attacks of late October 2016 have demonstrated, this oversight can ...
Machine Learning helps make complex systems more efficient. By applying advanced Machine Learning techniques such as Cognitive Fingerprinting, wind project operators can utilize these tools to learn from collected data, detect regular patterns, and optimize their own operations. In his session at 18th Cloud Expo, Stuart Gillen, Director of Business Development at SparkCognition, discussed how research has demonstrated the value of Machine Learning in delivering next generation analytics to impr...
Join Impiger for their featured webinar: ‘Cloud Computing: A Roadmap to Modern Software Delivery’ on November 10, 2016, at 12:00 pm CST. Very few companies have not experienced some impact to their IT delivery due to the evolution of cloud computing. This webinar is not about deciding whether you should entertain moving some or all of your IT to the cloud, but rather, a detailed look under the hood to help IT professionals understand how cloud adoption has evolved and what trends will impact th...